The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the impact of venetoclax combinations on the QoL of unfit, elderly patients with AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Keith Pratz, University of Pennsylvania, Philadelphia, US, about the impact of venetoclax combinations on the quality of life (QoL) of unfit, elderly patients with AML.

What is the impact of venetoclax combinations on the QoL of unfit, elderly patients with AML?

In this video, Pratz discusses the results of a study evaluating the impact of venetoclax addition to azacitidine (Viale-A study) or low-dose cytarabine (Viale-C study) on QoL, irrespective of response to therapy.

Share: